Unknown

Dataset Information

0

T cell responses to SARS-CoV-2 spike cross-recognize Omicron.


ABSTRACT: The SARS-CoV-2 Omicron variant (B.1.1.529) has multiple spike protein mutations1,2 that contribute to viral escape from antibody neutralization3-6 and reduce vaccine protection from infection7,8. The extent to which other components of the adaptive response such as T cells may still target Omicron and contribute to protection from severe outcomes is unknown. Here we assessed the ability of T cells to react to Omicron spike protein in participants who were vaccinated with Ad26.CoV2.S or BNT162b2, or unvaccinated convalescent COVID-19 patients (n = 70). Between 70% and 80% of the CD4+ and CD8+ T cell response to spike was maintained across study groups. Moreover, the magnitude of Omicron cross-reactive T cells was similar for Beta (B.1.351) and Delta (B.1.617.2) variants, despite Omicron harbouring considerably more mutations. In patients who were hospitalized with Omicron infections (n = 19), there were comparable T cell responses to ancestral spike, nucleocapsid and membrane proteins to those in patients hospitalized in previous waves dominated by the ancestral, Beta or Delta variants (n = 49). Thus, despite extensive mutations and reduced susceptibility to neutralizing antibodies of Omicron, the majority of T cell responses induced by vaccination or infection cross-recognize the variant. It remains to be determined whether well-preserved T cell immunity to Omicron contributes to protection from severe COVID-19 and is linked to early clinical observations from South Africa and elsewhere9-12.

SUBMITTER: Keeton R 

PROVIDER: S-EPMC8930768 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

T cell responses to SARS-CoV-2 spike cross-recognize Omicron.

Keeton Roanne R   Tincho Marius B MB   Ngomti Amkele A   Baguma Richard R   Benede Ntombi N   Suzuki Akiko A   Khan Khadija K   Cele Sandile S   Bernstein Mallory M   Karim Farina F   Madzorera Sharon V SV   Moyo-Gwete Thandeka T   Mennen Mathilda M   Skelem Sango S   Adriaanse Marguerite M   Mutithu Daniel D   Aremu Olukayode O   Stek Cari C   du Bruyn Elsa E   Van Der Mescht Mieke A MA   de Beer Zelda Z   de Villiers Talita R TR   Bodenstein Annie A   van den Berg Gretha G   Mendes Adriano A   Strydom Amy A   Venter Marietjie M   Giandhari Jennifer J   Naidoo Yeshnee Y   Pillay Sureshnee S   Tegally Houriiyah H   Grifoni Alba A   Weiskopf Daniela D   Sette Alessandro A   Wilkinson Robert J RJ   de Oliveira Tulio T   Bekker Linda-Gail LG   Gray Glenda G   Ueckermann Veronica V   Rossouw Theresa T   Boswell Michael T MT   Bhiman Jinal N JN   Moore Penny L PL   Sigal Alex A   Ntusi Ntobeko A B NAB   Burgers Wendy A WA   Riou Catherine C  

Nature 20220131 7901


The SARS-CoV-2 Omicron variant (B.1.1.529) has multiple spike protein mutations<sup>1,2</sup> that contribute to viral escape from antibody neutralization<sup>3-6</sup> and reduce vaccine protection from infection<sup>7,8</sup>. The extent to which other components of the adaptive response such as T cells may still target Omicron and contribute to protection from severe outcomes is unknown. Here we assessed the ability of T cells to react to Omicron spike protein in participants who were vaccina  ...[more]

Similar Datasets

| EMPIAR-10947 | biostudies-other
| S-EPMC8938268 | biostudies-literature
| EMPIAR-11180 | biostudies-other
| EMPIAR-11179 | biostudies-other
| EMPIAR-11176 | biostudies-other
| EMPIAR-11177 | biostudies-other
| S-EPMC8784649 | biostudies-literature
| EMPIAR-11871 | biostudies-other
| S-EPMC9272674 | biostudies-literature
| S-EPMC10782855 | biostudies-literature